抗生素
重症监护医学
抗生素耐药性
葡萄球菌感染
利奈唑啉
达巴万星
微生物学
替加环素
作者
Marisa Holubar,Long Meng,William Alegria,Stan Deresinski
标识
DOI:10.1016/j.idc.2020.04.003
摘要
Vancomycin and daptomycin are options for the initial treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia.
科研通智能强力驱动
Strongly Powered by AbleSci AI